Given the involvement of ONECUT2 in lineage plasticity driving neuroendocrine differentiation [40], the combination therapy of DAC and enzalutamide is a promising therapeutic strategy, especially by directly targeting ONECUT2 in PCa. The gene discussed is ONECUT2; the disease is posterior cortical atrophy.